Print page Print page
Switch language
The Capital Region of Denmark - a part of Copenhagen University Hospital

Cardiovascular biomarkers in clinical studies of type 2 diabetes

Research output: Contribution to journalReviewpeer-review


  1. Beta-hydroxybutyrate suppresses hepatic production of the ghrelin receptor antagonist, LEAP2

    Research output: Contribution to journalJournal articlepeer-review

  2. THERAPY OF ENDOCRINE DISEASE: Amylin and calcitonin - physiology and pharmacology

    Research output: Contribution to journalReviewpeer-review

  3. LEAP2 reduces postprandial glucose excursions and ad libitum food intake in healthy men

    Research output: Contribution to journalJournal articlepeer-review

View graph of relations

When planning cardiovascular studies in type 2 diabetes, selection of cardiovascular biomarkers is a complex issue. Since the pathophysiology of cardiovascular disease in type 2 diabetes is multifactorial, ideally, the selected cardiovascular biomarkers should cover all aspects of the known pathophysiology of the disease. This will allow the researcher to distinguish between effects on different aspects of the pathophysiology. To this end, we will discuss a host of biomarkers grouped according to their role in the pathogenesis of CV disease, namely: 1) cardiac damage biomarkers 2) inflammatory biomarkers and 3) novel biomarkers (oxidative stress and endothelial dysfunction biomarkers). Within each category we present the currently best validated biomarkers with special focus on the population of interest (type 2 diabetes). For each individual biomarker, the physiological role, the validation in the general population and in type 2 diabetes, analytical methodology, the modifying factors, the effects of glucose-lowering drugs, and the interpretation are discussed. This approach will provide clinical researchers with all information necessary for planning, conducting and interpreting results from clinical trials. Furthermore, a systematic approach to selection of cardiovascular biomarkers in type 2 diabetes research will improve the quality of future research.

Original languageEnglish
JournalDiabetes, Obesity and Metabolism
Issue number6
Pages (from-to)1350–1360
Number of pages10
Publication statusPublished - Jun 2018

    Research areas

  • Journal Article, Review

ID: 52758782